The same combination of T-DM1 and atezolizumab was explored in a randomized, placebo-controlled phase II trial (KATE 2), which recruited 202 patients with advanced HER2 positive BC, previously treated with trastuzumab and a taxane. Here, ERBB2 is linked to breast cancer.